myelodysplastic syndrome
Conditions
Interventions
Case series:decitabine and umbilical cord blood
Sponsors
Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai Institute of Hematology
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1. MDS diagnosed by both morphology and immunology; 2. Aged 18 to 60 years; 3.Liver and renal function: serum bilirubin<=35umol/L, AST/ALT lower than 2* upper normal serum level, creatinine<=150umol/L; 4. Normal cardiac function; 5. Performance status: Eastern Cooperative Oncology Group (ECOG) 0-2; 6. Signed written informed consent.
Exclusion criteria
Exclusion criteria: 1. Treatment related MDS; 2. Previously treated patients; 3. Allergy to any medication in the regimen; 4. Contraindications to chemotherapy drugs; 5. Abnormal liver and kidney function, exceeding the entry criteria; 6. Severe heart disease, including myocardial infarction, heart failure; 7. Patients with a "currently active" second malignancy; 8. Patients with "currently active" tuberculosis. Patients with HIV; 9. Patients with other hematological disease; 10. Pregnant or breastfeeding women; 11. Patients who can't understand or obey the protocol; 12. Past history of intolerance or allergy to similar drugs; 13. Patients participated in other clinical trial; 14. Other circumstance that obstructs the clinical trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Complete Remission Rate;Disease Free Survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall Survival;Minimal Residual Disease;Safety and Toxicity; | — |
Countries
China
Contacts
Public ContactJunmin Li
Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai Institute of Hematology
Outcome results
None listed